1. Home
  2. JAGX vs XRTX Comparison

JAGX vs XRTX Comparison

Compare JAGX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • XRTX
  • Stock Information
  • Founded
  • JAGX 2013
  • XRTX 2011
  • Country
  • JAGX United States
  • XRTX Canada
  • Employees
  • JAGX N/A
  • XRTX N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • XRTX Pharmaceuticals and Biotechnology
  • Sector
  • JAGX Health Care
  • XRTX Health Care
  • Exchange
  • JAGX Nasdaq
  • XRTX Nasdaq
  • Market Cap
  • JAGX 3.4M
  • XRTX 3.4M
  • IPO Year
  • JAGX N/A
  • XRTX N/A
  • Fundamental
  • Price
  • JAGX $2.30
  • XRTX $0.96
  • Analyst Decision
  • JAGX Strong Buy
  • XRTX
  • Analyst Count
  • JAGX 1
  • XRTX 0
  • Target Price
  • JAGX $60.00
  • XRTX N/A
  • AVG Volume (30 Days)
  • JAGX 97.0K
  • XRTX 231.8K
  • Earning Date
  • JAGX 08-12-2025
  • XRTX 08-13-2025
  • Dividend Yield
  • JAGX N/A
  • XRTX N/A
  • EPS Growth
  • JAGX N/A
  • XRTX N/A
  • EPS
  • JAGX N/A
  • XRTX N/A
  • Revenue
  • JAGX $11,552,000.00
  • XRTX N/A
  • Revenue This Year
  • JAGX $22.41
  • XRTX N/A
  • Revenue Next Year
  • JAGX $30.00
  • XRTX N/A
  • P/E Ratio
  • JAGX N/A
  • XRTX N/A
  • Revenue Growth
  • JAGX 13.93
  • XRTX N/A
  • 52 Week Low
  • JAGX $2.27
  • XRTX $0.80
  • 52 Week High
  • JAGX $110.75
  • XRTX $2.98
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 28.65
  • XRTX 51.52
  • Support Level
  • JAGX $2.28
  • XRTX $0.84
  • Resistance Level
  • JAGX $2.79
  • XRTX $0.97
  • Average True Range (ATR)
  • JAGX 0.14
  • XRTX 0.08
  • MACD
  • JAGX 0.09
  • XRTX 0.00
  • Stochastic Oscillator
  • JAGX 3.92
  • XRTX 48.11

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: